TO-O-1004 for Post-Operative Pain and Inflammation with Cataract Surgery
According to the WHO, patients suffering from cataract were reaching 65 millionsa，and the disease has been the number one cause of blindnessb.
Inflammation and pain are two prevalent findings after ocular surgeries, including cataract surgery. Therefore, to control post-surgical inflammation and pain, corticosteroids are widely administrated as a core treatment. However, improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, increase of intraocular pressure and the negative impact of preservatives used in many of these eye drops, has made a genuine motive for novel therapies development for post-surgical carec .
TO-O-1004 eye drops is in early stage of pre-clinical study.Ref:
a.World report on vision. Geneva: WHO; 2019.
b. Lancet Glob Health 2021; 9: e144-60.
c. Comm Eye Health Vol. 28 No. 90 2015 pp 32-33